NASDAQ:LBPS

4D pharma - LBPS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Today's Range: $1.65
▼
$1.65
50-Day Range: $1.56
▼
$3.40
52-Week Range: $1.50
▼
$11.09

Volume: N/A
Average Volume: N/A
Market Capitalization: $37.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About 4D pharma

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Receive LBPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

LBPS Stock News Headlines

June 28, 2022 | seekingalpha.com

4D pharma stock to be delisted from Nasdaq after co was placed into administration

June 28, 2022 | finance.yahoo.com

4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

August 17, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

May 26, 2022 | finance.yahoo.com

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 19, 2022 | finance.yahoo.com

4D pharma to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 | marketwatch.com

4D pharma Shares Rise on Encouraging Results From Asthma Treatment Trial

May 17, 2022 | nasdaq.com

4D Pharma Presents Data Supporting Potential Of MRx-4DP0004 As Oral Treatment For Asthma

April 1, 2022 | proactiveinvestors.com

4D Pharma has a busy year ahead after a successful 12 months of clinical research

August 17, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

March 31, 2022 | seekingalpha.com

4D pharma reports FY results

March 31, 2022 | finance.yahoo.com

4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

March 23, 2022 | seekingalpha.com

4D pharma stock soars 56% as drug combo meets efficacy goal early in kidney cancer group

March 12, 2022 | seekingalpha.com

ACHR,EBON and GENI among pre market gainers

February 23, 2022 | proactiveinvestors.com

4D pharma gets green light for phase I clinical trial of Parkinson's disease candidates

February 22, 2022 | msn.com

4D Pharma To Test Its Single-Strain Live Biotherapeutics In Parkinson's Disease

February 22, 2022 | morningstar.com

4D Pharma Shares Rise as Parkinson's Trial Receives FDA Clearance

February 22, 2022 | finance.yahoo.com

4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease

January 28, 2022 | benzinga.com

4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy

January 27, 2022 | seekingalpha.com

4D Pharma reports additional positive data from Part A of mid-stage asthma drug trial

January 27, 2022 | finance.yahoo.com

4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma

January 27, 2022 | proactiveinvestors.com

4D pharma hails 'highly encouraging' data from its early-stage asthma trial

January 20, 2022 | finance.yahoo.com

4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004

January 8, 2022 | nasdaq.com

4d Pharma Plc - ADR Shares Near 52-Week Low - Market Mover

January 5, 2022 | finanznachrichten.de

4D pharma plc: 4D pharma to Present at the H.C. Wainwright BioConnect Conference

January 5, 2022 | finance.yahoo.com

4D pharma to Present at the H.C. Wainwright BioConnect Conference

December 14, 2021 | proactiveinvestors.com

4D pharma 'couldn't have hoped for more at this stage' from live biotherapeutic for asthma

December 13, 2021 | proactiveinvestors.com

4D pharma says asthma live biotherapeutic shows ‘promising’ early signs of clinical activity

See More Headlines

Receive LBPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

LBPS Company Calendar

Today: 8/17/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LBPS
CUSIP: N/A
CIK: 1830162
Web: www.4dpharmaplc.com
Phone: 44-0-11-3895-0130
Fax: N/A
Employees: 92
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 5.21
Quick Ratio: 5.21

Sales & Book Value

Annual Sales: $720,000.00
Price / Sales: 51.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.44 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 22,540,000
Free Float: 11,810,000
Market Cap: $37.19 million
Optionable: Not Optionable
Beta: 0.97

Key Executives

Mr. Duncan Joseph Peyton (Age 52)
CEO & Exec. Director
Comp: $302.79k
Dr. Alexander James Stevenson Ph.D. (Age 50)
Chief Scientific Officer & Exec. Director
Comp: $259.88k
Mr. John Brendan Doyle (Age 44)
Chief Financial Officer
Ms. Fay Weston
Head of Investor Relations
Mr. Adrian Murray
Gen. Counsel (Interim)
Mr. Glenn Dourado
Exec. VP of Corp. Devel.
Ms. Lucy Christie
VP of HR
Mr. Christophe Carite
Sr. VP of CMC & Process Devel.
Ms. Imke Mulder
Exec. VP of Research

Key Competitors

View All Competitors

LBPS Stock - Frequently Asked Questions

Should I buy or sell 4D pharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D pharma in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LBPS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LBPS, but not buy additional shares or sell existing shares.
View LBPS analyst ratings or view top-rated stocks.
What is 4D pharma's stock symbol?: 4D pharma trades on the NASDAQ under the ticker symbol "LBPS."

What is 4D pharma's stock price today?: One share of LBPS stock can currently be purchased for approximately $1.65.
How much money does 4D pharma make?: 4D pharma (NASDAQ:LBPS) has a market capitalization of $37.19 million and generates $720,000.00 in revenue each year.
How can I contact 4D pharma?: 4D pharma's mailing address is 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ. The official website for the company is www.4dpharmaplc.com. The company can be reached via phone at 44-0-11-3895-0130 or via email at ir@4dpharmaplc.com.

This page (NASDAQ:LBPS) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms